Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.64
RHHVF's Cash to Debt is ranked higher than
62% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.19 vs. RHHVF: 0.64 )
RHHVF' s 10-Year Cash to Debt Range
Min: 0.36   Max: No Debt
Current: 0.64

Equity to Asset 0.34
RHHVF's Equity to Asset is ranked higher than
50% of the 756 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. RHHVF: 0.34 )
RHHVF' s 10-Year Equity to Asset Range
Min: 0.1   Max: 0.59
Current: 0.34

0.1
0.59
F-Score: 8
Z-Score: 4.88
M-Score: -2.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 34.30
RHHVF's Operating margin (%) is ranked higher than
98% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.96 vs. RHHVF: 34.30 )
RHHVF' s 10-Year Operating margin (%) Range
Min: 4.53   Max: 35.01
Current: 34.3

4.53
35.01
Net-margin (%) 23.15
RHHVF's Net-margin (%) is ranked higher than
96% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.39 vs. RHHVF: 23.15 )
RHHVF' s 10-Year Net-margin (%) Range
Min: -13.67   Max: 30.16
Current: 23.15

-13.67
30.16
ROE (%) 56.81
RHHVF's ROE (%) is ranked higher than
99% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.37 vs. RHHVF: 56.81 )
RHHVF' s 10-Year ROE (%) Range
Min: -16.17   Max: 71.47
Current: 56.81

-16.17
71.47
ROA (%) 17.58
RHHVF's ROA (%) is ranked higher than
97% of the 814 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.13 vs. RHHVF: 17.58 )
RHHVF' s 10-Year ROA (%) Range
Min: -5.78   Max: 17.58
Current: 17.58

-5.78
17.58
ROC (Joel Greenblatt) (%) 79.20
RHHVF's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.57 vs. RHHVF: 79.20 )
RHHVF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 6.9   Max: 84.52
Current: 79.2

6.9
84.52
EPS Growth (%) 8.60
RHHVF's EPS Growth (%) is ranked higher than
76% of the 626 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. RHHVF: 8.60 )
RHHVF' s 10-Year EPS Growth (%) Range
Min: -3.8   Max: 341.1
Current: 8.6

-3.8
341.1
» RHHVF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

RHHVF Guru Trades in

RHHVF Guru Trades in

Q2 2012

RHHVF Guru Trades in Q2 2012

Steven Romick 1,950,000 sh (+550%)
» More
Q3 2012

RHHVF Guru Trades in Q3 2012

Tom Russo 1,425 sh (New)
PRIMECAP Management 10,573,717 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with RHHVF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 20.20
RHHVF's P/E(ttm) is ranked higher than
89% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 41.40 vs. RHHVF: 20.20 )
RHHVF' s 10-Year P/E(ttm) Range
Min: 13.29   Max: 53.68
Current: 20.2

13.29
53.68
P/B 10.60
RHHVF's P/B is ranked higher than
52% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.26 vs. RHHVF: 10.60 )
RHHVF' s 10-Year P/B Range
Min: 2.64   Max: 22.21
Current: 10.6

2.64
22.21
P/S 4.80
RHHVF's P/S is ranked higher than
66% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.61 vs. RHHVF: 4.80 )
RHHVF' s 10-Year P/S Range
Min: 2.21   Max: 6.45
Current: 4.8

2.21
6.45
PFCF 17.50
RHHVF's PFCF is ranked higher than
95% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. RHHVF: 17.50 )
RHHVF' s 10-Year PFCF Range
Min: 8.19   Max: 39.65
Current: 17.5

8.19
39.65
EV-to-EBIT 13.88
RHHVF's EV-to-EBIT is ranked higher than
90% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.26 vs. RHHVF: 13.88 )
RHHVF' s 10-Year EV-to-EBIT Range
Min: 7.9   Max: 32
Current: 13.88

7.9
32
Shiller P/E 23.40
RHHVF's Shiller P/E is ranked higher than
88% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 97.53 vs. RHHVF: 23.40 )
RHHVF' s 10-Year Shiller P/E Range
Min: 13.9   Max: 110.34
Current: 23.4

13.9
110.34
Current Ratio 1.85
RHHVF's Current Ratio is ranked higher than
64% of the 809 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.28 vs. RHHVF: 1.85 )
RHHVF' s 10-Year Current Ratio Range
Min: 1.55   Max: 3.75
Current: 1.85

1.55
3.75
Quick Ratio 1.48
RHHVF's Quick Ratio is ranked higher than
67% of the 809 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.75 vs. RHHVF: 1.48 )
RHHVF' s 10-Year Quick Ratio Range
Min: 1.28   Max: 3.22
Current: 1.48

1.28
3.22

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.10
RHHVF's Dividend Yield is ranked higher than
88% of the 493 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.34 vs. RHHVF: 3.10 )
RHHVF' s 10-Year Dividend Yield Range
Min: 0.74   Max: 3.79
Current: 3.1

0.74
3.79
Dividend Payout 0.63
RHHVF's Dividend Payout is ranked higher than
75% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.21 vs. RHHVF: 0.63 )
RHHVF' s 10-Year Dividend Payout Range
Min: 0.21   Max: 0.59
Current: 0.63

0.21
0.59
Dividend growth (3y) -7.30
RHHVF's Dividend growth (3y) is ranked higher than
71% of the 360 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. RHHVF: -7.30 )
RHHVF' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 27.3
Current: -7.3

0
27.3
Yield on cost (5-Year) 2.54
RHHVF's Yield on cost (5-Year) is ranked higher than
78% of the 500 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.42 vs. RHHVF: 2.54 )
RHHVF' s 10-Year Yield on cost (5-Year) Range
Min: 0.61   Max: 3.11
Current: 2.54

0.61
3.11
Share Buyback Rate -0.20
RHHVF's Share Buyback Rate is ranked higher than
81% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.10 vs. RHHVF: -0.20 )
RHHVF' s 10-Year Share Buyback Rate Range
Min: 78.7   Max: -0.8
Current: -0.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 22.13
RHHVF's Price/Tangible Book is ranked higher than
55% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.76 vs. RHHVF: 22.13 )
RHHVF' s 10-Year Price/Tangible Book Range
Min: 4.05   Max: 95.2
Current: 22.13

4.05
95.2
Price/DCF (Projected) 2.04
RHHVF's Price/DCF (Projected) is ranked higher than
86% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.71 vs. RHHVF: 2.04 )
RHHVF' s 10-Year Price/DCF (Projected) Range
Min: 1.27   Max: 7.13
Current: 2.04

1.27
7.13
Price/Median PS Value 1.18
RHHVF's Price/Median PS Value is ranked higher than
74% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.24 vs. RHHVF: 1.18 )
RHHVF' s 10-Year Price/Median PS Value Range
Min: 0.75   Max: 1.26
Current: 1.18

0.75
1.26
Price/Graham Number 4.41
RHHVF's Price/Graham Number is ranked higher than
71% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.69 vs. RHHVF: 4.41 )
RHHVF' s 10-Year Price/Graham Number Range
Min: 1.78   Max: 7.97
Current: 4.41

1.78
7.97
Earnings Yield (Greenblatt) 7.20
RHHVF's Earnings Yield (Greenblatt) is ranked higher than
85% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. RHHVF: 7.20 )
RHHVF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.1   Max: 12.7
Current: 7.2

3.1
12.7
Forward Rate of Return (Yacktman) 3.74
RHHVF's Forward Rate of Return (Yacktman) is ranked higher than
76% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.19 vs. RHHVF: 3.74 )
RHHVF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 4.2   Max: 146.2
Current: 3.74

4.2
146.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, NVS, ABT » details
Traded in other countries:RO.Switzerland, ROG.Switzerland, RHO6.Germany, RHO5.Germany, RHO.Germany, 0QQ6.UK, 0QOK.UK, ROG N.Mexico
Roche was founded in 1896 and is headquartered in Basel, Switzerland and is a pharmaceutical and diagnostics company. It researches and produces medicines in oncology, infectious diseases, immunology, metabolism and neuroscience. Roche also participates in in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management. Genentech, in the United States, and Chugai Pharmaceuticals are subsidiaries of the Roche Group. The firm's business is segmented into the dharmaceuticals business and the diagnostics Business.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK